The effects of the dual 5α‐reductase inhibitor dutasteride on localized prostate cancer—results from a 4‐month pre‐radical prostatectomy study

@article{Gleave2006TheEO,
  title={The effects of the dual 5$\alpha$‐reductase inhibitor dutasteride on localized prostate cancer—results from a 4‐month pre‐radical prostatectomy study},
  author={Martin E. Gleave and Junqi Qian and Cal Andreou and Peter J. Pommerville and J. Chin and Rowan G. Casey and Gary Steinhoff and Neil E. Fleshner and David G. Bostwick and Lynn N. Thomas and R. Rittmaster},
  journal={The Prostate},
  year={2006},
  volume={66}
}
As dihydrotestosterone (DHT) is the most potent androgen in the prostate, inhibition of the 5α‐reductase isoenzymes, which convert testosterone to DHT, could be an appropriate target for the treatment of prostate cancer. 

Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5α‐reductase

The objective of this review is to provide an understanding of the pharmacological properties and the potential clinical benefits of 5AR inhibition.

Association of 5α‐reductase inhibitor use and pathological features of prostate cancer in men undergoing radical prostatectomy

The association of 5α‐reductase inhibitor (5‐ARI) treatment with pathologic and biochemical outcome among the contemporary prostate cancer patients undergoing radical prostatectomy is investigated.

5α- Reductase Inhibitors in Prostate Cancer: An Overview

A brief account of biology of prostate, rationale and efficacy of 5AR inhibitors in prostate cancer management and their associated controversies is given.

Effect of Steroid 5α-Reductase Inhibitors on Markers of Tumor Regression and Proliferation in Prostate Cancer

The results from the PCPT demonstrated that inhibition of 5αR may prevent or delay prostate cancer in some patients and it is also clear that suppression of DHT formation with a 5 αR inhibitor may cause regression of prostatic carcinomas.

The Rationale for Inhibiting 5 α - Reductase Isoenzymes in the Prevention and Treatment of Prostate Cancer

The inhibition of 5 α -reductase represents a valid target for prostate cancer risk reduction and treatment strategies and the greater suppression of dihydrotestosterone observed with agents that inhibit each 5 α reductase isoenzyme may translate into enhanced outcomes and studies are under way to test this hypothesis.

Role of 5α-reductase inhibitors in benign prostatic diseases

This review will discuss the important clinical trials of 5α-reductase inhibitors in the treatment of benign prostatic diseases and the role of dihydrotestosterone in these patients.

The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme?

Dutasteride provides greater suppression of DHT than finasteride, thereby underlying the hypothesis that inhibition of both type 1 and type 2 would provide correspondingly greater protection than inhibition of type 2 alone.

Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study

The Avodart after Radical Therapy for prostate cancer Study (ARTS), investigating the use of dutasteride to prevent or delay disease progression in patients with biochemical recurrence after therapy with curative intent.

5-Alpha-Reductase Inhibition as a Secondary Preventive Strategy

5-Alpha-reductase inhibitors (5-ARIs) block the conversion of testosterone to dihydrotestosterone, thereby reducing prostate volume and prostate-specific antigen (PSA). There is evidence that its use
...

References

SHOWING 1-10 OF 40 REFERENCES

Effect of early treatment of prostate cancer with the 5α‐reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats

This work evaluated the preventive effect of turosteride when administered during the latency period in this prostatic tumor model and found it to be effective.

Effect of turosteride, a 5α‐reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma

Turosteride (FCE 26073) is a new, potent, and selective 5α‐reductase inhibitor. We have investigated its effect on tumor growth, organ weight, and serum hormone levels in rats bearing the androgen

Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.

It is suggested that short-term treatment with dutasteride can cause regression in some prostate cancers, and dual inhibition of both isoenzymes may be more effective than suppression of 5alphaR2 alone in prostate cancer treatment or prevention.

Response of rat and human prostatic cancers to the novel 5α‐reductase inhibitor, SK&F 105657

A major decrease was a major decrease in tissue dihydrotestosterone (DHT) content in both tumors and both responded to SK&F 105657 treatment with a reproducible inhibition of tumor growth.

THE EFFECTS OF 5α-REDUCTASE INHIBITORS ON THE NATURAL HISTORY, DETECTION AND GRADING OF PROSTATE CANCER: CURRENT STATE OF KNOWLEDGE

ABSTRACTPurpose: The Prostate Cancer Prevention Trial (PCPT) showed that the 5α-reductase inhibitor (5ARI) finasteride significantly decreased the 7-year period prevalence of prostate cancer vs

Cell proliferation and apoptosis in prostate tumors and adjacent non‐malignant prostate tissue in patients at different time‐points after castration treatment

The mainstay treatment for advanced prostate cancer is radiotherapy with androgen ablation, but the short‐term cellular effects are largely unknown.

The influence of finasteride on the development of prostate cancer.

Finasteride prevents or delays the appearance of prostate cancer, but this possible benefit and a reduced risk of urinary problems must be weighed against sexual side effects and the increased risk of high-grade prostate cancer.

Randomized, placebo‐controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks

To measure expression of vascular endothelial growth factor (VEGF) and microvessel density (MVD) in the prostates of men after transurethral resection of the prostate (TURP) following 2 weeks of

Comparison of microvessel densities in rat prostate tissues treated with finasteride, bicalutamide and surgical castration: A preliminary study

If any one type of the hormonal intervention is superior in terms of the suppression of microvessel formation in the prostate in patients with benign prostate hyperplasia is identified.